PGE2 treatment did not elevate Foxo3a/β-catenin binding in Gdpd3+/+ LT-CML stem cells (Fig. 8b; Supplementary Fig. 15). This evidence concerns the gene GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive.